Acadian Asset Management
CNST

Acadian Asset Management’s Constellation Pharmaceuticals, Inc. CNST Stock Holding History

Acadian Asset Management’s Portfolio CNST Stock Details CNST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-4,984
Closed -$61K – 2078
2019
Q2 		$61K Buy
+4,984
New +$55.5K ﹤0.01% 1447

Other funds holding CNST

PS
Peter Svennilson $1.23B AUM 301.34% 1-Year Est. Return
TG
TRV GP Boston, Massachusetts $18.9M AUM 541.67% 1-Year Est. Return
ROTUOC
Regents of the University of California Oakland, California $3.01B AUM 11.91% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management's CNST Position: Q3 2019 in Review

Acadian Asset Management sold out of Constellation Pharmaceuticals, Inc. (CNST) in Q3 2019, closing a stake of 4,984 shares — an estimated $61K sold.

Acadian Asset Management first reported a position in CNST in Q2 2019 and held it in 1 quarter. The position peaked at $61K in Q2 2019. 48 funds tracked by Wall St. Rank hold CNST as of Q3 2019.

  • Acadian Asset Management reported no remaining Constellation Pharmaceuticals, Inc. position as of Q3 2019 after selling out during the quarter.
  • Acadian Asset Management sold 4,984 Constellation Pharmaceuticals, Inc. shares in Q3 2019, an estimated $61K.
  • Acadian Asset Management first reported a position in Constellation Pharmaceuticals, Inc. in Q2 2019 and held it in 1 quarter.
  • Acadian Asset Management's Constellation Pharmaceuticals, Inc. position peaked at $61K in Q2 2019.
  • 48 funds tracked by Wall St. Rank held Constellation Pharmaceuticals, Inc. as of Q3 2019.

Based on Acadian Asset Management's 13F filing for Q3 2019, filed 7 Nov 2019.